计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170840-100μg |
100μg |
现货 ![]() |
| |
| Ab170840-1mg |
1mg |
现货 ![]() |
| |
| Ab170840-5mg |
5mg |
现货 ![]() |
| |
| Ab170840-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Codrituzumab (anti-GPC3), 糖蛋白 3 抗体 |
|---|---|
| 别名 | 考曲妥珠单抗 | Codrituzumab(抗 GPC3) |
| 英文别名 | DGSX antibody | Glypican proteoglycan 3 antibody | Glypican-3 [Precursor] antibody | Gpc3 antibody | GPC3_HUMAN antibody | GTR2 2 antibody | GTR2-2 antibody | Heparan sulphate proteoglycan antibody | Intestinal protein OCI 5 antibody | Intestinal protein |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | GPC3 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 糖蛋白 3 抗体 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 28.4 kDa (Light Chain) & 52.6 kDa (Heavy Chain), under reducing conditions; 178.1 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1365267-33-9 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Codrituzumab (anti-GPC3) (Ab170840) - ELISA
Immobilized Human GPC3-his at 2 μg/mL can bind Codrituzumab (anti-GPC3) (Ab170840) with the EC₅₀ of 15.34 ng/mL.
Codrituzumab (anti-GPC3) (Ab170840) - SEC
The purity of Codrituzumab (anti-GPC3) (Ab170840) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 | |
| 分析证书 | Ab170840 |
| 1. Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K et al.. (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.. Anticancer Drugs, 21 (10): (907-16). [PMID:20847643] |
| 2. Davoodi J, Kelly J, Gendron NH, MacKenzie AE. (2007) The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26.. Proteomics, 7 (13): (2300-10). [PMID:17549790] |
| 3. Pilia, G G and 9 more authors.. (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome.. Nature genetics, [PMID:8589713] |
| 4. Shen, T T and 6 more authors.. (1997) Mapping of the Simpson-Golabi-Behmel overgrowth syndrome gene (GPC3) to chromosome X in human and rat by fluorescence in situ hybridization.. Mammalian genome : official journal of the International Mammalian Genome Society, [PMID:9021160] |
| 5. Lage, H H and Dietel, M M.. (1997) Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5.. Gene, (1): [PMID:9133586] |
| 6. Huber, R R and 8 more authors.. (1997) Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3 (GPC3) gene.. Genomics, (1): [PMID:9339360] |
| 7. Veugelers, M M and 11 more authors.. (2000) Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene.. Human molecular genetics, (22): [PMID:10814714] |
| 8. Capurro, Mariana M and 6 more authors.. (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.. Gastroenterology, [PMID:12851874] |
| 9. De Cat, Bart B and 8 more authors.. (2003) Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements.. The Journal of cell biology, (10): [PMID:14610063] |
| 10. Hippo, Yoshitaka Y and 19 more authors.. (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.. Cancer research, (1): [PMID:15059894] |
| 11. Ross, Mark T MT and 281 more authors.. (2005) The DNA sequence of the human X chromosome.. Nature, (17): [PMID:15772651] |
| 12. Capurro, Mariana I MI, Xiang, Yun-Yan YY, Lobe, Corrinne C and Filmus, Jorge J.. (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.. Cancer research, (15): [PMID:16024626] |
| 13. Capurro, Mariana I MI, Shi, Wen W, Sandal, Shaifali S and Filmus, Jorge J.. (2005) Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.. The Journal of biological chemistry, (16): [PMID:16227623] |
| 14. Capurro, Mariana M, Martin, Tonya T, Shi, Wen W and Filmus, Jorge J.. (2014) Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.. Journal of cell science, (1): [PMID:24496449] |
| 15. Capurro, Mariana M, Shi, Wen W, Izumikawa, Tomomi T, Kitagawa, Hiroshi H and Filmus, Jorge J.. (2015) Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling.. The Journal of biological chemistry, (20): [PMID:25653284] |
| 16. Tagliabracci, Vincent S VS and 14 more authors.. (2015) A Single Kinase Generates the Majority of the Secreted Phosphoproteome.. Cell, (18): [PMID:26091039] |
| 17. Saad, Ahmad A and 7 more authors.. (2018) Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells.. Biochemistry, (20): [PMID:29345911] |